Streetbeat News

Earnings

SLN

Silence Therapeutics (NASDAQ:SLN) has received mixed analyst ratings over the past quarter, with a shift from bullish to somewhat bullish sentiments in the last 30 days. The average 12-month price target for SLN has increased to $60.57, reflecting a 38.45% rise from the previous target. Analysts from firms like Morgan Stanley, HC Wainwright & Co., Chardan Capital, and BMO Capital have maintained or raised their ratings and price targets, indicating a positive outlook on the company's performance despite its financial challenges, including a significant revenue decline and below-average returns on equity and assets.

Portfolio Pulse from Benzinga Insights

April 22, 2024 | 6:00 pm

PG

Procter & Gamble (NYSE:PG) reported Q3 FY24 earnings with a 1% sales growth to $20.195 billion, missing estimates but beating EPS forecasts with $1.52. The company maintained its FY24 sales growth guidance and raised its EPS growth outlook. Shares rose 1.9% to $161.09. Jefferies and Deutsche Bank adjusted their price targets on P&G following the earnings announcement.

Portfolio Pulse from Avi Kapoor

April 22, 2024 | 5:54 pm

SLB

Schlumberger N.V. (NYSE:SLB) reported a 13% year-over-year increase in Q1 2024 revenue to $8.707 billion, surpassing consensus estimates. Adjusted EPS rose 19% Y/Y to 75 cents, meeting expectations. The company saw growth across all segments, with a notable 18% increase in international revenue. Despite a 6% decline in North American market revenue, CEO Olivier Le Peuch remains optimistic about global revenue growth, particularly with the contribution from the ChampionX acquisition. SLB announced a quarterly dividend of 27.5 cents per share. Following the earnings announcement, several analysts revised their price targets for SLB, with most maintaining a positive outlook but slightly lowering their targets.

Portfolio Pulse from Avi Kapoor

April 22, 2024 | 5:48 pm

SNAP

Investors have shown a bullish stance on Snap Inc. (NYSE:SNAP) through significant options trading activity, with a sentiment split of 65% bullish and 29% bearish. The options market indicates an expected price window for SNAP between $9.0 to $35.0. The largest trades include both bullish and bearish positions, with a notable volume and open interest in options within the mentioned price range. Snap, known for its social networking app Snapchat, has over 400 million daily active users, with North America accounting for a significant portion of its sales. The stock is currently trading at $11.11, with an RSI indicating a neutral position and an earnings announcement expected in 3 days. Analysts have given SNAP an average target price of $12.5.

Portfolio Pulse from Benzinga Insights

April 22, 2024 | 5:46 pm

BIDU

Financial analysts observed a bullish trend in Baidu's (NASDAQ:BIDU) options trading, with a significant portion of trades being calls over puts. The trading activity suggests a price target range between $50.0 and $120.0. Baidu, a dominant player in China's internet search market, has seen its stock price increase by 2.88%, with a current price of $97.79. The company is expected to announce earnings in 24 days, and a professional analyst from Citigroup has set a target price of $176.0, maintaining a Buy rating.

Portfolio Pulse from Benzinga Insights

April 22, 2024 | 5:45 pm

SOFI

Recent unusual options activity in SoFi Technologies (NASDAQ:SOFI) indicates a bearish sentiment among investors, with 63% of trades being bearish. The activity suggests an expected price range of $7.0 to $13.0 for SOFI over the next three months. The largest trades include both puts and calls, with a notable bearish put at a strike price of $13.00 expiring on 06/21/24. SoFi, a financial-services company, is expanding its offerings beyond student loan refinancing. The current market status shows SOFI's price at $7.21, with an upcoming earnings announcement. Analysts have issued mixed ratings with a consensus target price of $10.125.

Portfolio Pulse from Benzinga Insights

April 22, 2024 | 5:45 pm

MSFT

Microsoft Corp. (NYSE:MSFT) is set to report its fiscal Q3 2024 earnings with expectations of significant growth. Analysts predict earnings per share of $2.83 and revenue of $60.769 billion, marking a 15.1% year-on-year increase in revenue and a 15.98% increase in earnings. Goldman Sachs highlights Microsoft's unique position to scale Gen-AI revenue, projecting a +15% revenue growth and a 28% Azure growth. The firm maintains a 'Buy' rating on MSFT, with a 12-month price target of $450, indicating a strong investment opportunity.

Portfolio Pulse from Piero Cingari

April 22, 2024 | 5:40 pm

PG

The Procter & Gamble Company (NYSE:PG) reported its fiscal third quarter financials, revealing a 1% increase in net sales to $20.20 billion, missing the expected $20.41 billion. However, net income rose 11% YoY to $3.75 billion, surpassing the estimate of $1.41 per share. Despite no price hikes in the quarter, prices were up 3% YoY. Organic sales expanded 3% YoY, but volume growth remained flat for the second consecutive quarter. P&G's beauty, grooming, and fabric and home business segments saw volume growth, while health care and baby, along with feminine and family care segments, saw declines. The company raised its full-year core net earnings per share growth forecast to 10-11% and maintained its sales growth forecast at 2-4%.

Portfolio Pulse from Upwallstreet

April 22, 2024 | 5:39 pm

NKGN

NKGen Biotech Inc (NASDAQ:NKGN) shares surged by 29.30% to $1.43 on Monday with a trading volume of 19.25 million, significantly higher than its 100-day average of 2.85 million. The increase comes without specific news to justify the price jump. The company is preparing to present its NK cell therapy developments for neurodegenerative diseases at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit. Earlier, NKGen Biotech secured $5 million in second-lien convertible loan funding, contributing to a total of approximately $4.75 million in gross cash proceeds for 2024. CEO Paul Song highlighted the company's focus on Phase 2 Alzheimer's clinical trials, a recent IND submission for Parkinson's disease, and a nearly 50% reduction in monthly operational and clinical trial expenses.

Portfolio Pulse from Vandana Singh

April 22, 2024 | 5:38 pm

AAPL

AMD

INTC

NVDA

QCOM

TSM

TSMC reported strong Q1 results, surpassing estimates due to high AI demand. Its customers, including NVIDIA, Apple, AMD, and Qualcomm, contribute to its growth. NVIDIA aims to expand into AI software services, mirroring TSMC's role in chip manufacturing. TSMC's Q2 guidance reflects strong demand but anticipates a slight margin decline due to an earthquake and higher costs, though with minimal revenue impact. TSMC plans to mass-produce more efficient 2-nanometer chips by 2025 and expects significant revenue growth from AI processors.

Portfolio Pulse from Upwallstreet

April 22, 2024 | 5:31 pm